Topics

Corvus Pharmaceuticals to Present Updated Data from CPI-006 Clinical Trial at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

20:00 EDT 2 Oct 2019 | Globe Newswire

BURLINGAME, Calif., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that it will present data from its Phase 1/1b clinical trial of CPI-006 at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting 2019 in National Harbor, Maryland, taking place November 6-10.

Corvus will present data on CPI-006 in an oral presentation and two poster sessions:

Oral Presentation:
Abstract O40:Immunobiology and clinical activity of CPI-006, an anti-CD73 antibody with immunomodulating properties in a phase 1/1b trial in advanced cancers.
Presenter:Jason J. Luke, M.D., FACP, Director of the Cancer Immunotherapeutics Center, Associate Professor of Medicine, the University of Pittsburgh Medical Center and Hillman Cancer Center
Session Title:Session 204: Immune Checkpoints: Newer Targets and Update on Combinations
Date and Time:Friday, November 8, 2019 from 3:45 pm – 4:00 pm ET
  
Poster Presentations:
Poster P125:Adenosine and AMP gene expression profiles predict response to adenosine pathway therapies and indicate a need for dual blockade of CD73 and A2AR with CD73 inhibitors.
Presenter:Stephen Willingham, PhD, Corvus Senior Scientist
Poster Session:Biomarkers, Immune Monitoring, and Novel Technologies
Date and Time:Friday, November 8, 2019 from 7:00 am – 8:00 pm ET
Location:Poster Hall: Prince George AB / Gaylord National Hotel & Convention Center
  
Poster P434:A phase 1/1b study to evaluate the humanized anti-CD73 antibody, CPI-006, as a single agent, in combination with CPI-444, and in combination with pembrolizumab in adult patients with advanced cancers.
Presenter:Mehrdad Mobasher, M.D., Corvus Vice President and Chief Medical Officer
Poster Session:Clinical Trial in Progress
Date and Time:Saturday, November 9, 2019 from 7:00 am – 8:30 pm ET
Location:Poster Hall: Prince George AB / Gaylord National Hotel & Convention Center

About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies. Corvus’ lead product candidates are ciforadenant (CPI-444), a small molecule inhibitor of the A2A receptor, and CPI-006, a humanized monoclonal antibody directed against CD73 that exhibits immunomodulatory activity and blockade of adenosine production. These candidates are being studied in ongoing Phase 1 and 2 clinical trials in patients with a wide range of advanced solid tumors. Ciforadenant is being evaluated in a successive expansion cohort trial examining its activity both as a single agent and in combination with an anti-PD-L1 antibody. CPI-006 is being evaluated in a multicenter Phase 1/1b clinical trial as a single agent, in combination with ciforadenant, and with pembrolizumab. The Company’s third clinical program, CPI-818, an oral, small molecule drug that has been shown to selectively inhibit ITK, is in a multicenter Phase 1/1b clinical trial in patients with several types of T-cell lymphomas. For more information, visit www.corvuspharma.com.

INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
650-900-4522
LLea@corvuspharma.com

MEDIA CONTACT:
Sheryl Seapy
W2O pure
+1 213-262-9390
sseapy@purecommunications.com

Primary Logo

NEXT ARTICLE

More From BioPortfolio on "Corvus Pharmaceuticals to Present Updated Data from CPI-006 Clinical Trial at the Society for Immunotherapy of Cancer (SITC) Annual Meeting"

Quick Search

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...